TABLE 1.
Baseline characteristics of patients included in study 1 and study 2
| Characteristic | Valueb |
|
|---|---|---|
| Study 1 | Study 2 | |
| Demographic | ||
| n | 341 | 603 |
| Age (yr) | 54 (17) | 62 (15) |
| Sex | ||
| Male | 199 (58.4%) | 409 (67.8%) |
| Female | 142 (41.6%) | 194 (32.2%) |
| Ht (cm) | 171 (11) | 171 (9) |
| Wt (kg) | 88 (31) | 76 (19) |
| Body surface area (m2) | 2.02 (0.36) | 1.89 (0.25) |
| Body mass index (kg/m2) | 30.3 (11.5) | 26.1 (6.1) |
| Clinical | ||
| Charlson comorbidity index | 4 (2, 7) | |
| Intensive care unit | 88 (66.2%) | 230 (38.1%) |
| eGFRa (ml/min/1.73 m2) | 78 (43) | 75 (35) |
| eGFR (ml/min) | 88 (49) | 81 (39) |
| Laboratory | ||
| Serum creatinine (mg/dl) | 1.46 (1.43) | 1.31 (1.23) |
| Total bilirubin (mg/dl) | 0.81 (0.99) | |
| Hemoglobin (g/dl) | 9.4 (1.9) | |
| Platelet count (103 cells/μl) | 279.5 (151.8) | |
a
The eGFR was calculated using the CKDEPI equation.
b
Data are presented as n (%), mean (standard deviation), or median (interquartile range). Study 1, toxicity; study 2, pharmacokinetics.